Olezarsen Shows Favorable Long-Term Safety, Hepatic Fat Trends Back to Baseline in 12-Month Data
IONS has more than doubled off its 52-week low of $34.775.
Summary
Ionis Pharmaceuticals reported 12-month MRI data for olezarsen, highlighting a favorable long-term safety profile and high patient retention. However, the data also showed mean hepatic fat fraction levels trending back toward baseline after 24 months of 80 mg treatment, with less pronounced reductions for patients who moved from 50 mg. This update follows an 8-K filed earlier today that characterized the long-term data as positive. The nuanced efficacy trend for hepatic fat, despite good safety, is a critical detail for investors to consider.
At the time of this announcement, IONS was trading at $73.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $34.78 to $86.74. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.